THE ROLE OF HEMOFILTRATION IN THE CRITICALLY-III INTENSIVE-CARE UNIT PATIENT - PRESENT AND FUTURE

被引：28

作者：

GROOTENDORST, AF ^{[1
]}

VANBOMMEL, EFH ^{[1
]}

机构：

[1] ST CLARA HOSP,DEPT INTENS CARE,ROTTERDAM,NETHERLANDS

来源：

BLOOD PURIFICATION | 1993年 / 11卷 / 04期

关键词：

CONTINUOUS HEMOFILTRATION; ACUTE RENAL FAILURE; SEPTIC SHOCK; MULTIPLE SYSTEM ORGAN FAILURE; MEDIATORS;

D O I：

10.1159/000170118

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The development of acute renal failure (ARF) in intensive care unit (ICU) patients carries a poor prognosis. Today, most cases are no longer an isolated organ dysfunction but are part of a multiple system organ failure syndrome. Recently developed renal replacement therapies allow adequate metabolic control, even in highly catabolic and hemodynamically unstable patients. Whether these newer continuous techniques have resulted in a better outcome of these patients is unclear. Recent data suggest a possible beneficial effect of hemofiltration on outcome of ICU patients and the course of human and experimental septic shock, which may be ascribed to the removal of inflammatory mediators. The purpose of this paper is to review the history of hemofiltration techniques and to assess their present and future role in the management of ICU patients. Although hemofiltration has been shown to improve hemodynamics of experimental septic shock, convincing evidence that hemofiltration improves outcome of ICU patients is lacking. Available data suggest that high ultrafiltrate volumes may be needed to achieve clinically important beneficial effects of hemofiltration in these patients. Prospective, randomized trials in homogeneous patient groups are needed to assess the role of hemofiltration in patients with septic shock or multiple system organ failure.

引用

页码：209 / 223

页数：15

共 64 条

[1]

Pine R.W., Wertz M.J., Lennard E.S., Dellinger E.P., Carrico J., Minshew B.H., Determinants of organ malfunction or death in patients with intraabdominal sepsis. A discriminant analysis, Arch Surg, 118, pp. 242-249, (1983)

[2]

Shoemaker W.C., Circulatory mechanisms of shock and their mediators, Crit Care Med, 15, pp. 787-794, (1987)

[3]

Edwards J.D., Brown G.C.S., Nightingale P., Slater R.M., Faragher E.B., The use of survivors’ cardiorespiratory values as therapeutic goals in septic shock, Crit Care Med, 17, pp. 1098-1103, (1989)

[4]

Bone R.C., The pathogenesis of sepsis, Ann Intern Med, 115, pp. 457-469, (1991)

[5]

Rackow E.C., Astiz M.E., Pathophysiology and treatment of septic shock, JAMA, 266, pp. 548-554, (1991)

[6]

Badr K.F., Kelley V.E., Renneke H.G., Brenner B.M., Roles for thromboxane A<sub>2</sub> and leukotrienes in endotoxin induced acute renal failure, Kidney Int, 30, pp. 474-480, (1986)

[7]

Klausner J.M., Paterson I.S., Goldman G., Kobzik L., Rodzen C., Lawrence R., Valein R., Shepro D., Hechtman H.B., Postischemic renal injury is mediated by neutrophils and leukotrienes, Am J Physiol, 256, pp. F794-F802, (1986)

[8]

Sieberth H.G., Kierdorf H., Is continuous hemofiltration superior to intermittent dialysis and haemofiltration treatment?, Adv Exp Med Biol, 260, pp. 181-192, (1989)

[9]

Ziegler E.J., McCuthan J.A., Glauser M.P., Fierer J., Glauser M.P., Sadoff J.C., Douglas H., Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli, N Engl J Med, 307, pp. 1225-1230, (1982)

[10]

Ziegler E.J., Fisher C.J., Sprung C.L., Straube R.C., Sadoff J.C., Foulke G.E., Treatment of gram negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A double-blind, placebo-controlled trial, N Engl J Med, 329, pp. 429-436, (1991)

← 1 2 3 4 5 6 7 →